10x Genomics, Inc.
TXG
$11.70
$0.232.01%
| Weiss Ratings | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.97 | |||
| Price History | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 8.53% | |||
| 30-Day Total Return | -21.00% | |||
| 60-Day Total Return | -27.55% | |||
| 90-Day Total Return | -24.47% | |||
| Year to Date Total Return | -17.55% | |||
| 1-Year Total Return | -70.61% | |||
| 2-Year Total Return | -76.12% | |||
| 3-Year Total Return | -82.71% | |||
| 5-Year Total Return | -82.08% | |||
| 52-Week High % Change | -72.70% | |||
| 52-Week Low % Change | 26.21% | |||
| Price | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $42.85 | |||
| 52-Week Low Price | $9.27 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 08, 2024 | |||
| Valuation | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.43B | |||
| Enterprise Value | 1.12B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.52 | |||
| Earnings Per Share Growth | -30.30% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.33 | |||
| Price/Book (Q) | 2.01 | |||
| Enterprise Value/Revenue (TTM) | 1.83 | |||
| Price | $11.70 | |||
| Enterprise Value/EBITDA (TTM) | -7.15 | |||
| Enterprise Value/EBIT | -5.82 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 121.60M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (925) 401-7300 | |||
| Address | 6230 Stoneridge Mall Road Pleasanton, CA 94588-3260 | |||
| Website | www.10xgenomics.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -31.51% | |||
| Profit Margin | -29.90% | |||
| Management Effectiveness | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.77% | |||
| Return on Equity | -- | |||
| Income Statement | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 610.79M | |||
| Total Revenue (TTM) | 610.79M | |||
| Revenue Per Share | $5.02 | |||
| Gross Profit (TTM) | 414.78M | |||
| EBITDA (TTM) | -156.58M | |||
| EBIT (TTM) | -192.46M | |||
| Net Income (TTM) | -182.63M | |||
| Net Income Avl. to Common (TTM) | -182.63M | |||
| Total Revenue Growth (Q YOY) | -10.30% | |||
| Earnings Growth (Q YOY) | -0.16% | |||
| EPS Diluted (TTM) | -1.52 | |||
| EPS Diluted Growth (Q YOY) | 2.35% | |||
| Balance Sheet | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 393.40M | |||
| Cash Per Share (Q) | $3.24 | |||
| Total Current Assets (Q) | 584.39M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 710.13M | |||
| Current Ratio (Q) | 4.968 | |||
| Book Value Per Share (Q) | $5.81 | |||
| Total Assets (Q) | 918.64M | |||
| Total Current Liabilities (Q) | 117.63M | |||
| Total Debt (Q) | 82.61M | |||
| Total Liabilities (Q) | 208.50M | |||
| Total Common Equity (Q) | 710.13M | |||
| Cash Flow | TXG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -32.63M | |||
| Cash from Financing (TTM) | 10.91M | |||
| Net Change in Cash (TTM) | -15.22M | |||
| Levered Free Cash Flow (TTM) | 60.14M | |||
| Cash from Operations (TTM) | 6.66M | |||
